Vanguard Capital Management
TOVX icon

Vanguard Capital Management’s Theriva Biologics TOVX Stock Holding History

Vanguard Capital Management’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$122K Buy
486,179
+293,775
+153% +$87.1K ﹤0.01% 3861
2026
Q1 		$37.7K Buy
+192,404
New +$37.9K ﹤0.01% 3948

Other funds holding TOVX

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return

Vanguard Capital Management's TOVX Position: Q2 2026 in Review

Vanguard Capital Management increased its Theriva Biologics (TOVX) stake by 153% in Q2 2026, buying an estimated $87.1K and bringing the position to 486,179 shares worth $122K. The position accounts for ﹤0.01% of the portfolio, ranked #3861.

Vanguard Capital Management first reported a position in TOVX in Q1 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Vanguard Capital Management held 486,179 shares of Theriva Biologics worth $122K as of Q2 2026.
  • Vanguard Capital Management bought 293,775 Theriva Biologics shares in Q2 2026, an estimated $87.1K.
  • Theriva Biologics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3861 holding.
  • Vanguard Capital Management first reported a position in Theriva Biologics in Q1 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.